{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T04:23:52Z","timestamp":1743049432910,"version":"3.40.3"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jval.2025.01.017","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T17:08:35Z","timestamp":1738861715000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring a Patient-Centered Methodology to Identify Suitable Proxy Conditions as a Source for Utility Data, Using Alopecia Areata as a Case Example"],"prefix":"10.1016","volume":"28","author":[{"given":"Alice M.","family":"Biggane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rowena","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masara","family":"Elgares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2025.01.017_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12963-016-0091-3","article-title":"Summarizing health-related quality of life (HRQOL): development and testing of a one-factor model","volume":"14","author":"Yin","year":"2016","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.jval.2025.01.017_bib2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.2147\/PPA.S282399","article-title":"Measuring patient quality of life following treatment for alopecia","volume":"15","author":"Thadanipon","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jval.2025.01.017_bib3","series-title":"Handbook of Disease Burdens and Quality of Life Measures","first-page":"87","article-title":"The EQ-5D health-related quality of life questionnaire","author":"Gusi","year":"2010"},{"year":"2022","series-title":"NICE Health Technology Evaluations: the Manual","key":"10.1016\/j.jval.2025.01.017_bib4"},{"issue":"12","key":"10.1016\/j.jval.2025.01.017_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1586\/1744666X.2015.1085306","article-title":"The role of lymphocytes in the development and treatment of alopecia areata","volume":"11","author":"Guo","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib6","first-page":"753","article-title":"The epidemiology of alopecia areata: a population-based cohort study in UK primary care","volume":"186","author":"Harries","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jval.2025.01.017_bib8","first-page":"397","article-title":"Epidemiology and burden of alopecia areata: a systematic review","volume":"8","author":"Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jval.2025.01.017_bib9","doi-asserted-by":"crossref","first-page":"c3671","DOI":"10.1136\/bmj.c3671","article-title":"Management of alopecia areata","volume":"341","author":"Harries","year":"2010","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2133.2012.10955.x","article-title":"British Association of Dermatologists\u2019 guidelines for the management of alopecia areata 2012","volume":"166","author":"Messenger","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","article-title":"\u201c\u2018You lose your hair, what\u2019s the big deal?\u2019 I was so embarrassed, I was so self-conscious, I was so depressed:\u201d a qualitative interview study to understand the psychosocial burden of alopecia areata","volume":"4","author":"Aldhouse","year":"2020","journal-title":"J\u00a0Patient Rep Outcomes"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jval.2025.01.017_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity","author":"Muntyanu","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.jval.2025.01.017_bib15","article-title":"Does the EQ-5D measure the full impact of alopecia areata on patients\u2019 health related quality of life?","volume":"26","author":"Lloyd","year":"2023","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2025.01.017_bib16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.11124\/JBIES-21-00242","article-title":"Best practice guidance and reporting items for the development of scoping review protocols","volume":"20","author":"Peters","year":"2022","journal-title":"JBI Evid Synth"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib19","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1477-7525-10-134","article-title":"Systematic review of health-related quality of life models","volume":"10","author":"Bakas","year":"2012","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.01.017_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40273-021-01115-5","article-title":"Systematic literature review to identify utility values in patients with spinal muscular atrophy (SMA) and their caregivers","volume":"40","author":"Sutherland","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/ijt.ijt_99_20","article-title":"Cumulative life course impairment of alopecia areata","volume":"12","author":"Burns","year":"2020","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jval.2025.01.017_bib22","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/DER.0000000000000486","article-title":"Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents","volume":"30","author":"Grant","year":"2019","journal-title":"Dermatitis"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjd.18780","article-title":"Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP)","volume":"183","author":"Howells","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12529-017-9677-9","article-title":"Validation of an Egyptian Arabic version of Skindex-16 and Quality of Life Measurement in Egyptian Patients with Skin Disease","volume":"25","author":"Essa","year":"2018","journal-title":"Int J Behav Med"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/jdv.13520","article-title":"Quality of life in patients with alopecia areata: a hospital-based cross-sectional study","volume":"30","author":"Jankovic","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1365-2133.1998.02511.x","article-title":"Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis","volume":"139","author":"Gupta","year":"1998","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib29","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaad.2020.06.047","article-title":"Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: a systematic review","volume":"85","author":"Toussi","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib30","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/jidsymp.2013.18","article-title":"Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data","volume":"16","author":"Shi","year":"2013","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"6","key":"10.1016\/j.jval.2025.01.017_bib31","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-3083.2001.00229.x","article-title":"The effect of hair loss on quality of life","volume":"15","author":"Williamson","year":"2001","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib33","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jdin.2020.07.001","article-title":"Burden of skin disease and associated socioeconomic status in Europe: an ecologic study from the Global Burden of Disease Study 2017","volume":"1","author":"Chu","year":"2020","journal-title":"JAAD Int"},{"issue":"8","key":"10.1016\/j.jval.2025.01.017_bib34","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/jdv.17370","article-title":"Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes","volume":"35","author":"Chernyshov","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jval.2025.01.017_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/1346-8138.16364","article-title":"Health-related quality of life in patients with alopecia areata: results of a Japanese survey with norm-based comparisons","volume":"49","author":"Ito","year":"2022","journal-title":"J\u00a0Dermatol"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jaad.2016.10.039","article-title":"Quality of life in adults with facial port-wine stains","volume":"76","author":"Hagen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2015.04.039","article-title":"Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden","volume":"73","author":"Hagstrom","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/bjd.13572","article-title":"Health-related quality of life in morphoea","volume":"172","author":"Klimas","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13555-018-0224-7","article-title":"A\u00a0qualitative investigation of the impact of acne on health-related quality of life (HRQL): development of a conceptual model","volume":"8","author":"Fabbrocini","year":"2018","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1203475420907088","article-title":"Identifying the impacts of acne: a Delphi survey of patients and clinicians","volume":"24","author":"Tan","year":"2020","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1203475418756379","article-title":"Development of a comprehensive quality-of-life measure for facial and torso acne","volume":"22","author":"McLellan","year":"2018","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jval.2025.01.017_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajp.2016.10.011","article-title":"Alexithymia in different dermatologic patients","volume":"25","author":"Dehghani","year":"2017","journal-title":"Asian J Psychiatry"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib43","first-page":"255","article-title":"Impact of different skin conditions on quality of life","volume":"148","author":"Sampogna","year":"2013","journal-title":"G\u00a0Ital Dermatol Venereol Organo Ufficiale Soc Ital Dermatol Sifilogr"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12325-019-01164-5","article-title":"Development of a conceptual model of chronic hand eczema (CHE) based on qualitative interviews with patients and expert dermatologists","volume":"37","author":"Grant","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s42358-018-0036-6","article-title":"The effects of cultural background on patient-perceived impact of psoriatic arthritis - a qualitative study conducted in Brazil and France","volume":"58","author":"Palominos","year":"2018","journal-title":"Adv Rheumatol"},{"issue":"6","key":"10.1016\/j.jval.2025.01.017_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/nmo.12565","article-title":"The intestinal Gas Questionnaire: development of a new instrument for measuring gas-related symptoms and their impact on daily life","volume":"27","author":"Chassany","year":"2015","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib47","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1111\/ajd.13809","article-title":"Bidirectional association between alopecia areata and irritable bowel syndrome: a nationwide population-based cohort study","volume":"63","author":"Dai","year":"2022","journal-title":"Australas J Dermatol"},{"issue":"10","key":"10.1016\/j.jval.2025.01.017_bib48","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s11136-022-03141-y","article-title":"A\u00a0qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis","volume":"31","author":"Rencz","year":"2022","journal-title":"Qual Life Res"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib49","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1515\/folmed-2017-0041","article-title":"Implementation of Instrument based on eight health related quality of life domains for measuring of willingness to pay for psoriasis treatment","volume":"59","author":"Dobrev","year":"2017","journal-title":"Folia Med"},{"issue":"8","key":"10.1016\/j.jval.2025.01.017_bib50","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jval.2013.10.003","article-title":"Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK","volume":"16","author":"Swinburn","year":"2013","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2025.01.017_bib51","first-page":"511","article-title":"Associations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areata","volume":"50","author":"Ghajarzadeh","year":"2012","journal-title":"Acta Med Iran"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib52","first-page":"2","article-title":"Comparative study of psychiatric morbidity and quality of life in psoriasis, vitiligo and alopecia areata","volume":"4","author":"Saleh","year":"2008","journal-title":"Dermatol Online J"},{"issue":"7","key":"10.1016\/j.jval.2025.01.017_bib53","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s13555-022-00752-8","article-title":"Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI)","volume":"12","author":"Kitchen","year":"2022","journal-title":"Dermatol and Ther"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/jdv.17813","article-title":"Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis","volume":"36","author":"Thyssen","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40257-021-00604-9","article-title":"Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes","volume":"22","author":"Silverberg","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib56","first-page":"491","article-title":"Economic evaluation of a JAK inhibitor compared to a monoclonal antibody for treatment of moderate-to-severe atopic dermatitis from a UK perspective","volume":"25","author":"Heinz","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib59","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s13555-023-00894-3","article-title":"Dupilumab demonstrates rapid onset of action in improving signs, symptoms and quality of life in adults with atopic dermatitis","volume":"13","author":"Augustin","year":"2023","journal-title":"Dermatol and Ther"},{"issue":"9","key":"10.1016\/j.jval.2025.01.017_bib60","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s13555-022-00791-1","article-title":"Dupilumab treatment of atopic dermatitis in routine clinical care: baseline characteristics of patients in the PROLEAD prospective, observational study","volume":"12","author":"Thaci","year":"2022","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jval.2025.01.017_bib61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s12325-021-01630-z","article-title":"Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US National Health and Wellness Survey analysis","volume":"38","author":"Kwatra","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","article-title":"The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey","volume":"11","author":"Girolomoni","year":"2021","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib63","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s13555-022-00700-6","article-title":"Clinical and humanistic burden of atopic dermatitis in Europe: analyses of the National health and wellness survey","volume":"12","author":"Luger","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jval.2025.01.017_bib64","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.18451","article-title":"Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the U.K. and the U.S.A","volume":"182","author":"Andersen","year":"2020","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jval.2025.01.017_bib65","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s11136-020-02499-1","article-title":"Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study","volume":"29","author":"Vilsboll","year":"2020","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10198-022-01460-y","article-title":"Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L descriptive systems and utilities in atopic dermatitis","volume":"24","author":"Koszoru","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"6S","key":"10.1016\/j.jval.2025.01.017_bib67","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1097\/DER.0000000000000908","article-title":"General and skin-specific health-related quality of life in patients with atopic dermatitis before and during the COVID-19 pandemic","volume":"33","author":"Koszoru","year":"2022","journal-title":"Dermatitis"},{"issue":"8","key":"10.1016\/j.jval.2025.01.017_bib68","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13555-022-00777-z","article-title":"Burden of moderate to severe atopic dermatitis in adults from France, Italy, and the UK: patient-reported outcomes and treatment patterns","volume":"12","author":"Kleyn","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jval.2025.01.017_bib69","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1684\/ejd.2021.4166","article-title":"Symptom burden of patients with moderate-to-severe atopic dermatitis","volume":"31","author":"Egeberg","year":"2021","journal-title":"Eur J Dermatol"},{"issue":"10","key":"10.1016\/j.jval.2025.01.017_bib70","first-page":"943","article-title":"Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study","volume":"19","author":"Lio","year":"2020","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"4","key":"10.1016\/j.jval.2025.01.017_bib71","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","article-title":"Health utility scores of atopic dermatitis in US adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.jval.2025.01.017_bib72","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2340\/00015555-2940","article-title":"Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study","volume":"98","author":"Misery","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.jval.2025.01.017_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaip.2022.10.032","article-title":"Patients\u2019 and caregivers\u2019 experiences with atopic dermatitis-related burden, medical care, and treatments in 8 countries","volume":"11","author":"Capozza","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.jval.2025.01.017_bib74","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/jdv.15223","article-title":"The impact of atopic dermatitis on sexual health","volume":"33","author":"Misery","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.jval.2025.01.017_bib75","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11136-019-02174-0","article-title":"Process utilities for topical treatment in atopic dermatitis","volume":"28","author":"Retzler","year":"2019","journal-title":"Qual Life Res"},{"issue":"12","key":"10.1016\/j.jval.2025.01.017_bib80","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s13555-023-01057-0","article-title":"Physician- and patient-reported severity and quality of life impact of alopecia areata: results from a real-world survey in five European countries","volume":"13","author":"Va\u00f1\u00f3-Galv\u00e1n","year":"2023","journal-title":"Dermatol Ther"},{"year":"2020","series-title":"Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results From an English Population Study","author":"Alava","key":"10.1016\/j.jval.2025.01.017_bib81"},{"issue":"6","key":"10.1016\/j.jval.2025.01.017_bib82","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s11136-024-03645-9","article-title":"Estimation of health utility values for alopecia areata","volume":"33","author":"Aggio","year":"2024","journal-title":"Qual Life Res"},{"author":"Biggane","key":"10.1016\/j.jval.2025.01.017_bib86"},{"year":"2023","series-title":"There\u2019s a sense of losing yourself and who you are:\u201d Development of a Conceptual Model via Literature and Interviews Points to Large Psychosocial Burden and Lower Health Related Quality of Life for UK Based Alopecia Patients With \u226550% Hair Loss","author":"Biggane","key":"10.1016\/j.jval.2025.01.017_bib87"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T22:24:06Z","timestamp":1743027846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1098301525000440"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.01.017","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring a Patient-Centered Methodology to Identify Suitable Proxy Conditions as a Source for Utility Data, Using Alopecia Areata as a Case Example","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}